Exchange: EURONEXT Industry: Biotechnology
-0.15% €1.326
America/New_York / 17 mai 2024 @ 11:35
FUNDAMENTALS | |
---|---|
MarketCap: | 133.33 mill |
EPS: | -0.220 |
P/E: | -6.03 |
Earnings Date: | May 14, 2024 |
SharesOutstanding: | 100.55 mill |
Avg Daily Volume: | 0.0408 mill |
RATING 2024-05-17 |
---|
B- |
Neutral |
RATINGS | ||
---|---|---|
Rating CashFlow: | Neutral | |
Return On Equity: | Strong Sell | |
Return On Asset: | Strong Sell | |
DE: | Neutral | |
P/E: | Sell | |
Price To Book: | Strong Buy |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
Revenue | ||||||
Gr.Profit | ||||||
Ebit | ||||||
Asset | n/a | n/a | n/a | |||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -6.03 | sector: PE 17.68 |
PE RATIO: COMPANY / INDUSTRY |
---|
0x |
Company: PE -6.03 | industry: PE -7.48 |
DISCOUNTED CASH FLOW VALUE |
---|
€0.0467 (-96.48%) €-1.279 |
Date: 2024-05-19 |
Expected Trading Range (DAY) |
---|
€ 1.258 - 1.402 ( +/- 5.41%) |
ATR Model: 14 days |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | €1.326 (-0.15% ) |
Volume | 0.0117 mill |
Avg. Vol. | 0.0408 mill |
% of Avg. Vol | 28.56 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % |
---|
Transgene SA, a biotechnology company, focuses on designing and developing therapeutic vaccines and oncolytic viruses for the treatment of cancer and infectious diseases. It is involved in developing TG4050, a therapeutic vaccine that is in phase I clinical trial for the treatment of ovarian cancer, and human papilloma virus (HPV)-negative head and neck cancers; TG4001, a therapeutic vaccine, which is in phase II clinical trial for the treatment of HPV-positive cancers; TG6002, an oncolytic virus that is in phase I/IIa clinical trial for the treatment of various solid tumors, such as gastrointestinal adenocarcinoma comprising stomach, pancreas, and colon; and BT-001, an oncolytic virus, which is in phase I/II clinical trial for the treatment of solid tumors. The company also develops TG1050, a therapeutic vaccine for the treatment of chronic hepatitis B; and Pexa-Vec, an oncolytic virus for the treatment of solid tumors. It has strategic collaboration agreements with AstraZeneca, Merck KGaA, Pfizer, PersonGen BioTherapeutics, and NEC Corporation; licensing agreements with SillaJen, Ascend BioPharmaceutical, and Valneva; and agreements with Sanofi, BioInvent, and Randox. The company was incorporated in 1979 and is headquartered in Illkirch-Graffenstaden, France. Transgene SA is a subsidiary of TSGH SAS.